Arcus Biosciences Inc (RCUS):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Arcus Biosciences Inc (RCUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8175)・商品コード:DATA904C8175
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:33
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Arcus Biosciences Inc (Arcus Biosciences) is a clinical stage bio-pharmaceutical company. The company develops and commercializes cancer immunotherapies. Its product pipeline includes AB928, which is in phase 1/1b trial; AB122 is being developed for cancer patients, is in Phase 1 trial; AB154, an anti-TIGIT antibody is in Phase 1 trial. In addition, the company also has small-molecule programs, which include AB680 (IV) in preclinical stage, AB680 (oral) in discovery stage. The company offers its products in areas of immunology, medicinal chemistry, biochemistry, enzymology, pharmacology and structural biology. Arcus Biosciences is headquartered in Hayward, California, the US.

Arcus Biosciences Inc (RCUS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arcus Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Arcus Biosciences Raises USD107 Million in Series C Financing 10
Arcus Biosciences Raises USD70 Million in Series B Financing 13
Arcus Biosciences Raises USD50 Million in Series A Financing 14
Partnerships 16
Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 16
Licensing Agreements 17
Taiho Pharma Enters into Licensing Agreement with Arcus Biosciences 17
Arcus Biosciences Enters into Licensing Agreement with Wuxi Biologics and Harbin Gloria Pharma for GLS-010 18
Arcus Biosciences Enters into Licensing Agreement with Abmuno Therapeutics 19
Equity Offering 20
Arcus Biosciences Raises USD138 Million in IPO 20
Pact Pharma Raises Funds through Private Placement of Shares 21
Arcus Biosciences Inc – Key Competitors 22
Arcus Biosciences Inc – Key Employees 23
Arcus Biosciences Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 06, 2018: Arcus Biosciences announces second quarter 2018 financial results and recent corporate updates 25
May 09, 2018: Arcus Biosciences Announces First Quarter 2018 Financial Results and Recent Corporate Updates 27
Corporate Communications 29
Jun 12, 2018: Arcus Biosciences Announces the Promotion of Jennifer Jarrett to Chief Operating Officer 29
Dec 18, 2017: Arcus Biosciences Appoints David Beier to Board of Directors 30
Sep 18, 2017: Arcus Biosciences Appoints Kate Falberg to Its Board of Directors 31
Clinical Trials 32
Jul 30, 2018: Arcus receives approval to start Phase l trial of AB154 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arcus Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arcus Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arcus Biosciences Raises USD107 Million in Series C Financing 10
Arcus Biosciences Raises USD70 Million in Series B Financing 13
Arcus Biosciences Raises USD50 Million in Series A Financing 14
Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 16
Taiho Pharma Enters into Licensing Agreement with Arcus Biosciences 17
Arcus Biosciences Enters into Licensing Agreement with Wuxi Biologics and Harbin Gloria Pharma for GLS-010 18
Arcus Biosciences Enters into Licensing Agreement with Abmuno Therapeutics 19
Arcus Biosciences Raises USD138 Million in IPO 20
Pact Pharma Raises Funds through Private Placement of Shares 21
Arcus Biosciences Inc, Key Competitors 22
Arcus Biosciences Inc, Key Employees 23

List of Figures
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arcus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Arcus Biosciences Inc (RCUS):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8175)販売に関する免責事項を必ずご確認ください。
★調査レポート[Arcus Biosciences Inc (RCUS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆